mark hoffman, ph.d. vp – cerner life sciences sept 4, 2009 shawnee mission south
TRANSCRIPT
Mark Hoffman, Ph.D.VP – Cerner Life Sciences
Sept 4, 2009
Shawnee Mission South
Bio-sketch
• Raytown South High School 1987
• BA - William Jewell College 1991– Oxford University 1990
• Ph.D. - University of Wisconsin 1996– 1994 internship at DNAStar
• Postdoctoral training – National Animal Disease Center (USDA) 1996-1997
High school
• Science Honor Society– Knowledge Bowl
• Equal interest in science and social studies
William Jewell College
• Oxbridge Honors Program– Molecular Biology Major– Semester in England studying bioethics
• Electives in political science– Cold War politics– International relations
Undergraduate summers
• UMKC– Learned how to do basic Microbiology tasks
• KU– Learned biochemical techniques– Protein purification– Small research problems
• Refolding of purified proteins
• JC Penney commission sales
University of Wisconsin
• Department of Bacteriology
• Funded by biotechnology training program– NIH program provides tuition and stipend for
first 3 years– Requires internship in industry– Coursework outside major
Graduate school
• Years 1-2 – Classes– Identify research project
• Preliminary exams• Years 3 – x
– Research– Publications– Write thesis– Defend thesis
Staphylococcal enterotoxin A
• Causes food poisoning
• Activates immune system through unusual mechanism
• Are the two related?
Rhesus monkey umbilical cordblood stimulation assay
Molecular modeling
Sites associated with vomiting Sites associated with immune activity
Internship
• DNAStar
• Developed programs that perform DNA and protein sequence analysis– Immunology related algorithms to predict
immunogenic epitopes in proteins• Rational vaccine design
NADC• National Animal Disease Center – USDA
• Ames, Iowa
• Research on diseases of importance to agriculture and human food safety
• Biosecurity level 2 and 3 barns
EC 0157:H7• E. coli O157:H7
– Causes enterohemorrhagic colitis– 7% of cases progress to hemolytic uremic
syndrome
• Live oral vaccination
Clin. Diag. Immun. 1998 5:242-246
Cerner
• Software developer for Microbiology team– Respond to issues– Write programs
• Team leader– Responsibilities above + lead team
• Architect• Solution Manager• Director• Vice President
Our VisionOur Vision• Begin where youwant to end:– Automate
enterprise workflow
– Connect the community
– Structure and analyze
– Create executable knowledge
• The objective: close the loop
Critical DecisionsCritical Decisions
.
Cerner Millennium Solutions PortfolioCerner Millennium Solutions Portfolio
Innovation You Can Trust™
©2003 Cerner Corporation. All rights reserved. This document contains confidential information which may not be reproduced or transmitted without the expressed written consent of Cerner.Version 3.0
Community &Consumer Systems
PhysicianPortal
PowerLink
ConsumerRelationshipManagement
ConditionCenters
Call Center Bio-SurveillanceHealthSentry
SpecialtyCare Systems
CardiologyCVNet
OncologyPowerChartOncology
Women’sHealth Children’s Orthopedics Pulmonology Home Health
ProCall
ClinicalCenter Systems Clinical TrialsLaboratory
PathNetRadiology
RadNetImage
ManagementCerner ProVision
PharmacyPharmNet
Financial & OperationalSystems
PatientAccounting
ProFit
CostAccounting
Supply ChainProCure
HealthInfo. Mgmt.
ProFile
WorkforceManagement
OutcomesMeasurement
PowerInsight
ComparativeData
HealthFacts
Knowledge-DrivenCare Solutions
DecisionSupport Engine
Discern Expert
ReportingDiscern Explorer
PowerVision
Outcomes & BenchmarkingCerner APACHE
DrugDatabase
Cerner Multum
ReferentialKnowledge
Zynx
ExecutableKnowledge
DirectCare Systems
EMRPowerChart
CDR
AmbulatoryCare
PowerChart OfficeEmergency
FirstNetCritical Care
INet
Surgery &Anesthesia
SurgiNet
Acute CareCareNet
PowerOrders
Plans & Protocol Mgmt.
PowerPlan
Multi-ContributorDocumentation
PowerNote &PowerForms
ConnectivityTechnologies
InterfaceEngine
Open Engine
InterfaceLibraryOpenPort
Medical DeviceInterfaces
ApplicationDev. Kit
MobileSolutions
Health Economy DistributedDatabase EMPI
DistributedDatabase EMR
Access SystemsEnterprise
Master PersonIndex
RegistrationEnterprise
Registration Mgmt.
SchedulingEnterprise
Scheduling Mgmt.
Benefits Mgmt.Eligibility &
Med. Necessity
Inherent SolutionsClosed LoopMed. Process Meds Integration
HIPAACompliance
ClinicalDecisionSupport
ClinicallyDriven Revenue
Cycle
Clinically DrivenResourcePlanning
IndustrialStrength Early Maturity 2003 2004 2005 FutureKey
10 Solution Groups – 54 Solutions
Millennium Helix™
Public Health
Lab Result
Fill Out Forms by Hand
Fax to DOH
Fill out Log for HIM – HIPAA Compliance
Follow Up from DOH
Preparation of Internal IC
Reports by hand using multiple
systems
Automatic Reporting - HealthSentry
Daily Reports for Lab and IC
“Pushed” to HealthSentry
users
Public Health
HealthSentry Architecture
Daily Result Trending
DATA COMPLETENESS Reportable cases (non-STD): March-Sept 2002
*Average over 6 key data fields
UNDER-REPORTING
0%
100%
200%
300%
400%
% I
nc
reas
e
0%
20%
40%
60%
80%
100%
Conventional HealthSentry
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Conventional HealthSentry
TIMELINESS
% F
ield
s C
om
ple
te
*Average over all reportables
*Increased overall reporting by 96%
Da
ys
to r
ece
ive
rep
ort
HealthSentry – Proven Results
Present role
• Director of Translational Medicine at Cerner Corporation– Genomics– Biobanking– Clinical Trials– Registries
• Lead group that is developing:– New software module(s)– Controlled vocabulary
• Scope:• Molecular pathology• Clinical Genetics• Infectious disease• Cytogenetics
• Current state (Jun 2007):• 10,714 Concepts• 25,246 Relationships• 709 Genes• 867 Nucleotide variants • 6,821 Terms
• 5,411 Facets
• Available from: www.clinbioinformatics.org
• Included in the NCI Metathesaurus
The Clinical Bioinformatics Ontology
Unified Report
Default- uneditable
MultiMedia Foundation (MMF)
Document Results
Protocol
Pharmacogenomics• Use of genetic information in the
selection of therapy.• Sometimes used to describe the
use of Genomics to identify drug targets.
• Mutations that affect ability to metabolize drugs– Adverse Reactions
• Halothane -> Malignant Hyperthermia - RYR1
– Dosage effects• Coumadin - CYP2C9
– No benefit• Codeine - CYP2D6
Partnership Developments
• Visual Technologies– Pedigree– Data exploration
Opportunities
• Internships (High School or College)
• Clinical roles– Nurse– Medtech– Physician
• Technical roles– Software engineer– Systems engineer
Decisions• Seemingly small decisions can have lasting
impact
• Try to open doors and avoid closing them
• A career in science doesn’t rule out:– Business– Policy– Management
• Never say “just” – about yourself or others
• Learn what you do well and what you don’t and then accept both